Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
40.29
+0.39 (0.98%)
Jan 17, 2025, 4:00 PM EST - Market closed
Revolution Medicines Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for RVMD stock have an average target of 65.15, with a low estimate of 42 and a high estimate of 87. The average target predicts an increase of 61.70% from the current stock price of 40.29.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RVMD stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 6 | 7 | 7 |
| Buy | 7 | 7 | 7 | 7 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $65 → $71 | Strong Buy | Maintains | $65 → $71 | +76.22% | Jan 8, 2025 |
| Wedbush | Wedbush | Buy Maintains $70 → $67 | Buy | Maintains | $70 → $67 | +66.29% | Dec 6, 2024 |
| Needham | Needham | Strong Buy Maintains $68 → $62 | Strong Buy | Maintains | $68 → $62 | +53.88% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $64 → $72 | Strong Buy | Maintains | $64 → $72 | +78.70% | Dec 4, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $82 → $87 | Strong Buy | Maintains | $82 → $87 | +115.93% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
327.86K
from 11.58M
Decreased by -97.17%
Revenue Next Year
6.41M
from 327.86K
Increased by 1,855.42%
EPS This Year
-3.55
from -3.86
EPS Next Year
-4.03
from -3.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.7M | 73.5M | 177.7M | |||
| Avg | 327,859 | 6.4M | 20.8M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -59.2% | 22,318.2% | 2,671.2% | |||
| Avg | -97.2% | 1,855.4% | 224.3% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.55 | -3.41 | -2.51 | |||
| Avg | -3.55 | -4.03 | -4.22 | |||
| Low | -3.90 | -4.56 | -4.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.